You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas
Nuwellis completes Rendiatech acquisition
Login
Username:

Password:


Related Headlines

IsomAb names new CEO

Elaris FlexCo signs global licence agreement with Valneva

Samsung Bioepis partners with Sandoz on up to five next-generation biosimilars

Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease

Nuwellis completes Rendiatech acquisition

Avacta opens Phase 1 trial for AVA6103 cancer therapy in US

Imfinzi approved in EU for perioperative treatment of early gastric and gastroesophageal cancers

26Health acquires Optimal Integrative Care

Vimgreen Pharmaceuticals receives IND clearance for VG081821 in China

Aditxt acquires Ignite Proteomics to enhance cancer therapy selection

Inimmune reports dosing of first patient in Phase 2 allergen challenge chamber trial of INI-2004

Andel launches new direct-to-employer medication platform for GLP-1s

Gesynta Pharma doses first patient in vipoglanstat Phase 2 clinical proof-of-concept trial

NASA awards Redwire USD4m to advance drug development in microgravity

Elicera Therapeutics receives Japanese patent allowance for ELC-401 CAR T-cell candidate

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026